UBE2C, ubiquitin conjugating enzyme E2 C, 11065

N. diseases: 105; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.100 Biomarker phenotype BEFREE <b>Background:</b> Recent evidence indicates that UBE2C participates in carcinogenesis by regulating the cell cycle, apoptosis, metastasis, and transcriptional processes. 31037155 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE 1.UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme, and its overexpression has been demonstrated in a variety of malignancies. 20529090 2010
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE Tumors with high Ube2c expression showed higher frequencies of tumor invasion to capsular formation (fc-inf), invasion to portal vein (vp) and tumor de-differentiation (p < 0.05). 17354233 2007
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 AlteredExpression group BEFREE Ube2c gene expression in the cancer tissue was higher than in the corresponding noncancerous tissue in 62 of the 65 cases (95.4%, p < 0.01). 17354233 2007
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 AlteredExpression group BEFREE Ube2c gene expression in the cancer tissue was higher than in the corresponding noncancerous tissue in 62 of the 65 cases (95.4%, p < 0.01). 17354233 2007
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 AlteredExpression group BEFREE UbcH10 expression was related to the grade of malignancy. 19438748 2009
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 AlteredExpression group BEFREE UbcH10 expression was related to the grade of malignancy. 19438748 2009
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme, and its overexpression has been demonstrated in a variety of malignancies. 19779934 2010
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 AlteredExpression group BEFREE UbcH10 is overexpressed in many human cancer types and is associated with tumor progression. 20065091 2010
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 AlteredExpression group BEFREE UbcH10 is overexpressed in many human cancer types and is associated with tumor progression. 20065091 2010
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.060 AlteredExpression phenotype BEFREE UbcH10 is overexpressed in many human cancer types and is associated with tumor progression. 20065091 2010
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE UbcH10 quantitative RT-PCR analysis, rather than immunohistochemistry, is useful to increase the detection of malignancy in thyroid FNAs. 20544706 2010
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 Biomarker group BEFREE UbcH10 quantitative RT-PCR analysis, rather than immunohistochemistry, is useful to increase the detection of malignancy in thyroid FNAs. 20544706 2010
CUI: C0007847
Disease: Malignant tumor of cervix
Malignant tumor of cervix 		0.030 Biomarker disease BEFREE UBE2C could be evaluated further to assess its potential as a therapeutic target in cervical cancer. 21338529 2011
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma 		0.030 Biomarker disease BEFREE UBE2C could be evaluated further to assess its potential as a therapeutic target in cervical cancer. 21338529 2011
CUI: C4048328
Disease: cervical cancer
cervical cancer 		0.030 Biomarker disease BEFREE UBE2C could be evaluated further to assess its potential as a therapeutic target in cervical cancer. 21338529 2011
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.060 AlteredExpression disease BEFREE UBE2C expression was an independent prognostic marker in early-stage (I and II) CRC. 21514426 2011
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.060 Biomarker disease BEFREE UBE2C) involved in prostate cancer growth through chromatin looping. 21889355 2011
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.060 Biomarker disease BEFREE UBE2C) involved in prostate cancer growth through chromatin looping. 21889355 2011
CUI: C1608408
Disease: Malignant transformation
Malignant transformation 		0.020 AlteredExpression phenotype BEFREE UBE2C expression is upregulated upon malignant transformation, and amplification of UBE2C is often seen at the chromosome level in cancers in a manner similar to c-Myc, which is directly upstream of UBE2C. 22170434 2012
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.020 AlteredExpression phenotype BEFREE UBE2C levels are upregulated in a wide range of solid tumors and hematological malignancies. 22170434 2012
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms 		0.010 AlteredExpression group BEFREE UBE2C levels are upregulated in a wide range of solid tumors and hematological malignancies. 22170434 2012
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE UBE2C immunochemistry may be integrated into the diagnosis of thyroid malignancy and gliomas. 22170434 2012
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 Biomarker group BEFREE UBE2C immunochemistry may be integrated into the diagnosis of thyroid malignancy and gliomas. 22170434 2012
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma 		0.010 AlteredExpression disease BEFREE UbcH10 is overexpressed in poorly differentiated NSCLC samples than in well-differentiated ones, and its expression level was significantly higher in squamous cell carcinoma than that in adenocarcinoma. 22760214 2012